On June 25, 2018, the U.S. Food and Drug Administration (FDA) announced its first-ever approval of a marijuana-derived pharmaceutical drug.
With Congress seemingly poised to legalize the cultivation of industrial hemp for many uses, including the production of biomass for CBD oil extraction, many questions remain unanswered. How will the DEA reschedule CBD now that Epidiolex has been approved as a pharmaceutical CBD isolate? To what extent will the FDA regulate hemp-derived CBD?
A series of police raids in North Dakota has set the stage for a courtroom showdown regarding the legal status of cannabidiol (CBD), the non-intoxicating cannabis component with significant medical properties. Thus far, it’s not going well for purveyors of the claim that hemp-derived CBD is legal in all 50 U.S. states.
Project CBD responds to the Food and Drug Administration’s call for statements on the use of CBD.
How will botanical CBD be regulated when cannabidiol is approved as a pharmaceutical?
In December of 2016, the DEA announced that it is implementing new rules that may portend a crackdown on CBD oil products. Misinformation claiming cannabidiol was legal was promoted by numerous online businesses. Educate yourself about the situation and what you can do.
Kratom is an unique medicinal herb with pain relieving properties that function as an opiate substitute. So why is the FDA and the DEA trying to block people’s access to it by making it a Schedule 1 drug?
Lab testing, safety protocols, adverse events reporting, and regulatory standards for the cannabis industry.
Project CBD science advisor Jahan Marcu, PhD, reports on the hidden dangers of propylene glycol and vape pens that smolder.